SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday, March 12, 2018 at the American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18), following the presentation of new interim data from the ongoing ANNEXA-4 Phase 3b/4 trial of the Company’s investigational Factor Xa reversal agent andexanet alfa, during the Late-Breaking Clinical Trials Session.
The conference call and live audio webcast will be hosted by Dr. C. Michael Gibson, ANNEXA-4 Executive Committee member, Harvard Medical School professor and chairman of the PERFUSE Study Group, who will provide an overview of the interim results presented during the Late-Breaking Clinical Trials Session. Dr. Gibson will be joined by Portola management for the Q&A portion of the call.
| ANNEXA-4 Late-Breaking Oral Presentation Details | |
| Session: | (409) Late-Breaking Clinical Trials Session: Interventional Cardiology |
| Title: | ANNEXA-4: Interim Report on the ANNEXA-4 Study: Andexanet for Reversal of |
| Anticoagulation in Factor Xa-Associated Acute Major Bleeding | |
| Presenter: | Stuart J. Connolly, M.D., Professor Emeritus of Medicine, McMaster University, Hamilton |
| Health Sciences | |
| Date: | Monday, March 12, 10:45 a.m. – 11:45 a.m. ET |
| Room: | ACC.18 Main Tent, Hall C |
Webcast and Conference Call Details
To access the investor webcast and presentation slides on Monday, March 12 at 12:30 p.m. ET (9:30 a.m. PT), go to the Investor Relations section of the company’s website at http://investors.portola.com. The live call can be accessed by phone by dialing (844) 452-6828 The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call. from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 8493604. Analysts and investors interested in attending the in-peron event in Orlando should RSVP to Cara Miller at cmiller@portola.com for additional details.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Laurie Masonson
W2O Group
lmasonson@w2ogroup.com